Hepatitis C in correctional institutions

Current Hepatitis Reports

Volumn 6, Issue 3, 2007, Pages 114-118

  Zaller, Nickolas D ^b   Taylor, Lynn E ^b   Allen, Scott ^b   Rich, Josiah D ^a  

^a MIRIAM HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ALCOHOL CONSUMPTION; DEPRESSION; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH PROMOTION; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; PATIENT CARE; PREVALENCE; PRISON; PSYCHOTHERAPY; PUBLIC HEALTH SERVICE; REVIEW; SCREENING; VACCINATION;

EID: 34848860177     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-007-0013-8     Document Type: Review

References (46)

1. Weinbaum C, Lyerla R, Margolis HS; Centers for Disease Control and Prevention: Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003, 52(RR-1):1-36.
2. Hammett TM, Harmon MP, Rhodes W: The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health 2002, 92:1789-1794.
3. Harrison PM, Beck AJ: Prisoners in 2004 (Pub. No. NCJ 210677). Washington DC: US Department of Justice; 2005.
4. Mumola C: Substance abuse and treatment, state and federal prisoners, 1997 (Pub. No. NCJ 172871). Washington, DC: US Department of Justice, Office of Justice Programs; 1999.
5. Rogers WB, Seigenthaler CP: Correctional health care as a vital part of community health. J Ambul Care Manage 2001, 24:45-50.
6. Kwiatkowski CF, Corsi KF, Booth RE: The association between knowledge of hepatitis C virus status and risk behaviors among injection drug users. Addiction 2002, 97:1289-1294.
7. Brau N, Salvatore M, Rios-Bedova CF, et al.: Slower fibrosis progression in HIV/HCV co-infected patients with successful HV suppression using antiretroviral therapy. J Hepatol 2006, 44:47-55. Explains that suppression of HIV in HIV/HCV coinfected patients can slow fibrosis in these patients. This has important implications for treatment of HIV/HCV coinfected individuals.
8. Macalino G, Dhawan D, Rich JD: A missed opportunity: hepatitis C screening of prisoners. Am J Public Health 2005, 95:1739-1740.
9. Spaulding AC, Weinbaum CM, Lau DT, et al.: A framework for management of hepatitis C in prisons. Ann Intern Med 2006, 144:762-769. An excellent overview of HCV infection in incarcerated settings, reviewing guidelines on testing and treatment of HCV infection among prison populations.
10. Spaulding A, Greene C, Davidson K, et al.: Hepatitis C in state correctional facilities. Prev Med 1999, 28:92-100.
11. Sterling RK, Hifnann CM, Sanyal AJ, et al.: Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: Can compliance overcome racial differences to response? Am J Gastroenterol 2004, 99:866-872. Excellent article illustrating that HCV treatment among inmates can have treatment response rates similar to those for persons treated in the community.
12. Wong JB, McQuillan GM, McHutchison JG, Poynard T: Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000, 90:1562-1569.
13. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002, 19:1-46.
14. Boutwell AE, Allen SA, Rich JD: Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis 2005, 40(suppl 5):S367-S372. Emphasizes that correctional institutions are a place of opportunity to provide testing, education, and, when appropriate, treatment for HCV infection.
15. Allen SA, Spaulding AC, Osei AM, et al.: Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003, 138:187-190.
16. Kraus MR, Schafer A, Al-Taie O, Scheurlen M: Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005, 12:96-100.
17. Hauser P, Khosla J, Aurora H, et al.: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002, 7:942-947.
18. Schaefer M, Heinz A, Backmund M: Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004, 99:1167-1175.
19. Hammet TM: HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden and appropriate response. Am J Public Health 2006, 96:974-978.
20. Hammet T: Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Ann Intern Med 2003, 138:235-236.
21. Weiss L, Kluger M, McCoy K: Health care accessibility among people that inject drugs or use crack cocaine. New York: Office of Special Populations, New York Academy of Medicine; 2000.
22. Falck-Ytter Y, Kale H, Mullen K, et al.: Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002, 136:288-292.
23. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
24. Sherer R: Adherence and antiretroviral therapy in injection drug users. JAMA 1998, 280:567-568.
25. Edlin BR, Seal KH, Lorvick J, et al.: Is it justifiable to withhold treatment for hepatitis C from illicit drug users? N Engl J Med 2001, 534:211-215.
26. Chaisson RE, Barnes GL, Hackman J, et al.: A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med 2001, 110:610-615.
27. Rich JD, Macalino GE, McKenzie M, et al.: Syringe prescription to prevent HIV infection in Rhode Island: a case study. Am J Public Health 2001, 91:699-700.
28. Dalgard O, Bjoro K, Hellum K, et al.: Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002, 8:45-49.
29. Asselah T, Vidaud D, Doloy A, et al.: Second infection with a different hepatitis C virus genotype in an intravenous drug user during interferon therapy. Gut 2003, 52:900-902.
30. Des Jarlais DC, McKnight C, Friedmann P: Legal syringe purchases by injection drug users, Brooklyn and Queens, New York City, 2000-2001. J Am Pharm Assoc (Wash) 2002, 42:S73-S76.
31. Management of Hepatitis C. NIH Consens Statement 1997, 15:1-41.
32. Davis GL, Rodrigue JR: Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001, 345:215-217.
33. Strader DB: Understudied populations with hepatitis C. Hepatology 2002, 36:S226-S236.
34. Backmund M, Meyer K, von Zeilonka M, Eichenlaub D: Treatment of hepatitis C infection in injection drug users. Hepatology 2001, 34:188-193.
35. Schaefer M, Schmidt F, Folwaczny C, et al.: Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003, 37:443-451.
36. Sylvestre DL: Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002, 67:117-123.
37. Hagan H, Des Jarlais DC, Friedman SR, et al.: Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Pub Health 1995, 85:1531-1537.
38. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998, 47(RR-19):1-39.
39. Pessione F, Ramond MJ, Peters L, et al.: Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking, and abstinence. Liver Int 2003, 23:45-53.
40. Harris HE, Ramsay ME, Andrews N, et al.: Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002, 324:450-453.
41. Jamal MM, Morgan TR: Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol 2003, 17:649-662.
42. Lubelczyk RAB, Friedmann PD, Lemon SC, et al.: HIV prevention services in correctional drug treatment programs: Do they change risk behaviors? AIDS Educ Prev 2002, 14:117-125.
43. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999, 48(RR-12):1-37.
44. Lee S, Chan C, Yu M, et al.: Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999, 59:463-468.
45. Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286-290.
46. Zarski J-P, Bohn B, Bastie A, et al.: Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998, 28:27-33.